The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

A comprehensive analysis conducted by public health experts at Novartis Romania reveals that Romanian patients may wait, on ...

A research team from the School of Clinical Medicine of the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) ...

Confirms Single Phase 3 Immuno-Bridging Trial Sufficient to Evaluate Efficacy and to Support a Marketing Authorization ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as ...

Ilunocitinib tablets are currently available in Brazil, Canada and Japan, in addition to the US. Elanco noted that, once the ...

BeOne Medicines (NASDAQ:ONC) gains FDA approval for a new tablet version of Brukinsa, simplifying dosage for patients.

Generic Drugs Market Size to Reach USD 769.52 Billion by 2033 | Says Cervicorn ConsultingThe generic drugs market size is ...

Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in ...